NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 53.98

-6.5%

Nov 13 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (162)	10/19/2006 10:06:50 AM
From: Arthur Radley	Read Replies (2) of 507

PFE announced Q 3 results today...interesting that they gave revenue numbers for Sutent that was approved after Exubera...but no revenue numbers given for Exubera and the product has been launched in Europe for months and here in Sept. ....NKTR is selling down this morning, so guess this is the reason. At this stage I think Sanofi is pleased they sold their position in the drug to PFE.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next